Skip to content

Consultbio: what changed

BE 1026.717.482NACE 72.101, Research and development on biotechnologyOther company

Position among the sector peers

What moved

Only one financial year

Comparing needs two financial years with figures read. This company has one.

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€244,620 to €329,574

Midpoint €280,018 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

Adjusted equity €64,468
Capitalised earnings €424,771 to €594,680
Indication €244,620 to €329,574

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€64,468
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€64,468

Capitalised earnings

net result for the year (9904)
2025
€59,468
Average result
€59,468
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€424,771 / €495,567 / €594,680

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The value is an indication, not a valuation or advice. Prepared on 17 November 2026 via checked.be.